Skip to main content

Table 1 Baseline patient characteristics of the included studies

From: A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms

References

No.

Sex (M/F)

Median age (years, range)

No. of PV

No. of ET

No. of PMF

Thrombotic outcome

Bleeding outcome

Study period

Type

Fenaux 1990 [7]

147

60/87

60 (18–83)

–

147

–

Yes (A + V)

Yes

1970–1987

R

Colombi 1991 [8]

103

44/59

59 (9–88)

–

103

–

Yes (A + V)

Yes

1975–1990

R

Besses 1999 [9]

148

53/95

60.5 (11–85)

–

148

–

Yes (A + V)

Yes

1979–1994

R

Manoharan 1999 [10]

61

PV: 10/ 10

ET: 10/ 20

PMF: 5/ 6

PV: 76 (54–84)

ET: 71 (25–88)

PMF: 74 (31–84)

20

30

11

Yes (A + V)

No

1993–1997

P

Jensen 2000 [11]

96

27/69

67 (18–87)

–

96

–

Yes (A + V)

Yes

1977–1998

R

Passamonti 2000 [12]

163

98/65

57 (30–82)

163

–

–

Yes (A + V)

Yes

1975–1997

R

Chim 2005 [13]

231

112/119

65 (18–90)

–

231

–

Yes (A + V)

Yes

NR

R

Marchioli 2005 [14]

1638

942/ 696

60.4

1638

–

–

Yes (A + V)

Yes

NR

P

Cervantes 2006 [15]

155

97/ 58

65 (17–89)

–

–

155

Yes (A + V)

No

1972–2005

R

Wolanskyj 2006 [16]

322

104/ 218

54 (12–88)

–

322

–

Yes (A + V)

Yes

1956–1992

R

Carobbio 2007 [17]

439

175/ 264

54 (10–93)

–

439

–

Yes (A + V)

No

1981–2006

R

Vannucchi 2007 [18]

962

PV: 176/ 147

ET: 202/ 437

NR

323

639

–

Yes (A + V)

No

NR

R

Bang 2009 [19]

283

143/ 140

61

120

NR

NR

Yes (A + V)

Yes

2006–2007

P

Barbui 2010 [20]

707

465/ 242

62 (11–90)

–

–

707

Yes (A + V)

No

1973–2008

R

Elliott 2010 [21]

205

131/ 74

62 (28–87)

–

–

205

Yes (A + V)

No

1982–2008

R

Palandri 2011 [22]

532

205/ 327

64 (16–95)

–

532

–

Yes (A + V)

No

1978–2008

R

Buxhofer-Ausch 2012 [23]

264

109/ 155

57.4

–

–

264

Yes (A + V)

No

NR

P

Finazzi 2012 [24]

1104

ET: 370/ 521

PMF: 74/ 106

ET: 55.7 (12.9–91)

PMF: 57.4 (20.9–87.7)

–

891

180

No

Yes

NR

P

Angona 2015 [25]

214

57/ 157

64 (9–93)

–

214

–

Yes (A + V)

No

1985–2012

R

Enblom 2015 [26]

612

PV: 131/ 118

ET: 117/ 155

PMF: 47/ 44

PV: 69

ET: 67

PMF: 71

249

272

91

Yes (A + V)

Yes

1995–2013

R

Lim 2015 [27]

102

54/ 48

64 (24–87)

33

69

–

Yes (A)

Yes

2004–2012

R

Duangnapasatit 2015 [28]

157

PV: 46/ 22

ET: 32/ 51

PMF: 4/ 2

PV: 59.6 (18–88)

ET: 61.1 (21–89)

PMF: 68.3 (52–78)

68

83

6

Yes (A + V)

Yes

2003–2013

R

Kaifie 2016 [29]

454

232/ 222

60

142

140

113

Yes (A + V)

Yes

NR

P

Cerquozzi 2017 [30]

587

284/ 303

60 (17–94)

587

–

–

Yes (A + V)

No

NR

P

Abdulkarim 2017 [31]

2389

PV: 548/557

ET: 534/750

PV: 69 (17–98)

ET: 68 (13–94)

1105

1284

–

Yes (A + V)

Yes

2008–2015

R

Soyer 2017 [32]

708

PV: 132/ 81

ET: 151/ 239

PMF: 56/ 49

PV: 47.5 (17–86)

ET: 41.5 (17–89)

PMF: 69.5 (19–87)

213

390

105

Yes (A + V)

Yes

1987–2014

R

Bertozzi 2017 [33]

253

NR

NR

124

121

8

Yes (A)

Yes

1978–2016

R

Zhou 2018 [34]

150

67/ 83

61 (41–71)

–

150

–

Yes (A + V)

No

2013–2016

P

Hintermair 2018 [35]

250

152/ 98

NR

NR

NR

NR

Yes (A + V)

No

2008–2015

R

  1. Abbreviations: A Artery, ET Essential thrombocythemia, F Female, M Male, NR Not reported, P Prospectively, PMF Primary myelofibrosis, PV Polycythemia vera, R Retrospectively, V Vein